Monte Rosa Presents Preclinical Data for MRT-8102 at ACR Convergence on November 9: the NEK7 Molecular Glue Degrader Inhibited NLRP3 Inflammasome Activation, With the GEMINI-1 Phase 2 Gout Study to Start in the Fourth Quarter of 2026
BOSTON — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) announced on November 9, 2026, the presentation of preclinical data at ACR Convergence 2026, held November 6–11 in Orlando, Florida, showing that MRT-8102, an orally bioavailable NEK7-directed molecular glue degrader, inhibited NLRP3 inflammasome activation in human experimental systems and reduced inflammation in a rabbit model of gouty arthritis.
The poster, titled "MRT-8102, an Orally Bioavailable NEK7-Selective Molecular Glue Degrader, Suppresses NLRP3 Inflammasome Activation and Demonstrates Efficacy in a Rabbit Model of Gouty Arthritis" (Poster #1082), was presented by Philippe Pagni, Ph.D., Director of Biology, during Poster Session B, "Innate Immunity," on November 9 from 10:30 a.m. to 12:30 p.m. Eastern time. The company said MRT-8102 reduced caspase-1 activity in human macrophages stimulated with monosodium urate (MSU) or calcium pyrophosphate dihydrate (CPPD) crystals, supporting its potential to address crystal-induced inflammation in gout and pseudogout.
The company said GEMINI-1, a Phase 2 study of MRT-8102 in patients with gout, is expected to initiate in the fourth quarter of 2026, will evaluate prevention of flare recurrence following acute flare management, and has initial data expected in the second half of 2027. In the release, Monte Rosa described itself as a clinical-stage biotechnology company developing novel molecular glue degrader-based medicines.
https://www.morningstar.com/news/globe-newswire/9872774/monte-rosa-therapeutics-presents-preclinical-data-at-acr-convergence-2026-on-the-potential-of-mrt-8102-in-gout （Monte Rosa 2026年11月9日经 GlobeNewswire 发布的临床前数据公告）
科学
—-
Published by GSM · USA (original Chinese edition)
Photo: Wikipedia/Wikimedia Commons 词条主图：Monte Rosa
